Hybrigenics and Dualsystems Enter Partnership for Yeast Two-Hybrid Screens of Full Membrane Proteins
News Jul 02, 2008
Yeast two-hybrid technology is widely and successfully used to identify protein interactions. However, some full membrane proteins are difficult to study with the gold standard methods, the company says.
The DUALmembrane yeast two-hybrid technology invented and patented by Dualsystems, based in Schlieren (Switzerland), has been especially designed to screen for membrane protein interactions. It is relevant for example for membrane receptors which represent as much as 40% of all targets for drugs on the market or still in pharmaceutical development.
Both Dualsystems and Hybrigenics will commercialize DUALmembrane screens. These will be performed exclusively on Hybrigenics' ISO 9001-certified industrial platform. This strategic partnership, based on a profit-sharing scheme, will boost Dualsystems' commercial and production volumes for its membrane technology, and will nicely complement Hybrigenics' wide range of protein interaction services offered to clients from all life sciences.
"We are delighted that our technology has been recognized as of special interest by Hybrigenics. DUALmembrane sales will certainly be boosted by this partnership." commented Daniel Auerbach, Dualsystems' CEO.
"We count on DUALmembrane to answer unmet service needs for membrane protein interactions, especially towards commercial prospects from the pharmaceutical industry." added Remi Delansorne, Hybrigenics' CEO. "We expect a positive contribution to our turnover from this new service”.
Lipid droplets have been found to play critical roles in the life cycles of certain proteins involved in gene expression. Now, a new study describes how lipid droplets regulate these proteins. The research has implications for understanding what helps embryos survive and could cause us to reconsider how we look at lipid-related diseases like obesity.READ MORE